The Saudi Food and Drug Authority (SFDA) has approved the medical device marketing authorization (MDMA) for a device that uses advanced deep brain stimulation technology. The SFDA described this technology as a breakthrough in neurological therapy, as it enables physicians to adjust treatment procedures in real time based on live brain signals detected during therapy. This allows for the personalization of treatment using data and algorithms, adapting to the patient’s changing condition.

The Saudi Food and Drug Authority (SFDA) has identified a defect in some of the Dexcom Continuous Glucose Monitoring (CGM) devices. This issue prevents audio alerts from sounding when blood glucose levels fluctuate too low or too high.

The Saudi Food and Drug Authority (SFDA) has suspended imports from an international medical device and supplies manufacturer. This action is part of its ongoing regulatory efforts to verify the safety of products under its supervision circulating in the Saudi market.

Operating around the clock, the Saudi Food and Drug Authority (SFDA), through its Hajj Operations Center, serves as a central point of contact to support field teams and ensure quick responses to reports throughout the Hajj season. This dedication aligns with the Authority's commitment to safeguarding the health and safety of pilgrims, reflecting the generous care extended by our wise leadership towards the pilgrims and their unwavering concern for their comfort and well-being.

As part of the Authority's ongoing efforts to ensure the safety and well-being of pilgrims, H.E. Prof. Dr. Hisham S. Aljadhey, Chief Executive Officer of the Saudi Food and Drug Authority (SFDA), conducted a field visit to the SFDA office in Makkah. The visit aimed to assess the implementation of operational plans for the 2025 Hajj season and confirm the readiness of services provided by the Authority to support a safe and healthy pilgrimage.

As part of its comprehensive preparations for the Hajj season 2025, the Saudi Food and Drug Authority (SFDA) has intensified its proactive inspection efforts, conducting over 1,329 field visits to food, pharmaceutical, and medical device warehouses in the Makkah and Madinah regions. This aligns with the remarkable compliance rates observed in facilities storing food and medicine, a direct result of ongoing inspections and awareness-raising efforts that have reinforced their commitment to the requirements.

The Saudi Food and Drug Authority (SFDA) has launched a digital awareness campaign to educate the public on the safe and proper use of medical devices and supplies intended for home use. This campaign aligns with the SFDA's ongoing commitment to public health and is a key component of its fourth strategic plan.

As part of its early and comprehensive preparations for the Hajj season 2025, the Saudi Food and Drug Authority (SFDA) has launched a series of field inspection tours across key locations and facilities. The purpose is to assess the state of readiness of the inspection teams and to monitor the implementation of approved plans, with the aim of protecting the health and safety of pilgrims by ensuring the highest standards of food, drug, and medical product safety.

The Saudi Food and Drug Authority (SFDA) is continuously advancing its regulatory framework and boosting its operational effectiveness. This aligns with the Health Sector Transformation Program, a key pillar of Saudi Vision 2030.

During the Hajj season, the SFDA intensifies its focus on employing technologies to protect pilgrim health and safety by providing top-tier quality control and regulatory services that meet the highest standards.